• Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF) CEO, Deborah Rathjen on the blood-brain barrier (Ep 44)

  • Jul 9 2021
  • Duración: 17 m
  • Podcast

Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF) CEO, Deborah Rathjen on the blood-brain barrier (Ep 44) Por arte de portada

Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF) CEO, Deborah Rathjen on the blood-brain barrier (Ep 44)

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Deborah Rathjen, CEO of Bioasis Technologies (BTI.V) talks about the company's ground-breaking xB3 platform which allows therapeutic drugs to pass through the seemingly impenetrable blood-brain barrier, providing an effective treatment methodology for such neurological disorders as Alzheimer's disease, Lewy Body Dementia and Parkinson's. In short, Bioasis' final frontier solution could very well revolutionize medical science, potentially helping to heal the one billion people suffering from neurological disorders worldwide. Tune in!
    Más Menos
activate_primeday_promo_in_buybox_DT
Economía Finanzas Personales
Más Menos

Lo que los oyentes dicen sobre Bioasis Technologies (TSX.V: BTI) (OTCQB: BIOAF) CEO, Deborah Rathjen on the blood-brain barrier (Ep 44)

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles